Breaking News Instant updates and real-time market news.

DB

Deutsche Bank

$6.93

(0.00%)

, BBD

Banco Bradesco

$7.87

(0.00%)

09:40
10/09/19
10/09
09:40
10/09/19
09:40

Unusually active option classes on open October 9th

Unusual total active option classes on open include: Deutsche Bank (DB), Banco Bradesco (BBD), Johnson & Johnson (JNJ), db X trackers China (ASHR), Activision Blizzard (ATVI), Roku (ROKU), NVIDIA (NVDA), and American Airlines (AAL).

DB

Deutsche Bank

$6.93

(0.00%)

BBD

Banco Bradesco

$7.87

(0.00%)

JNJ

Johnson & Johnson

$131.84

(0.00%)

ASHR

X-trackers Harvest CSI 300

$26.82

(0.00%)

ATVI

Activision Blizzard

$54.10

(0.00%)

ROKU

Roku

$108.06

(0.00%)

NVDA

Nvidia

$177.21

(0.00%)

AAL

American Airlines

$26.26

(0.00%)

  • 11

    Oct

  • 11

    Oct

  • 15

    Oct

  • 18

    Oct

  • 04

    Nov

  • 05

    Nov

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

DB Deutsche Bank
$6.93

(0.00%)

07/12/19
07/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Buy from Neutral at Goldman Sachs with analyst Judy Hong saying the valuations in the tobacco sector are trading at a 10-year trough in spite of the "more accommodating" macro backdrop for Consumer Staples that includes a late cycle and lower yields. 2. Focus Financial (FOCS) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Deutsche Bank (DB) upgraded to Neutral from Sell at UBS. 4. Morgan Stanley (MS) upgraded to Buy from Neutral at Citi. 5. Snap (SNAP) upgraded to Buy from Neutral at Goldman Sachs with analyst Heath Terry saying the company's new Android app, the launch of Snap Games, and new viral lenses should accelerator user growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
UBSW
07/12/19
UPGRADE
UBSW
Neutral
Deutsche Bank upgraded to Neutral from Sell at UBS
UBS upgraded Deutsche Bank to Neutral from Sell following the recent selloff in the shares.
07/08/19
BOFA
07/08/19
NO CHANGE
BOFA
Underperform
BofA keeps Underperform rating on Deutsche Bank, says capital still an issue
After Deutsche Bank released its outline of its new plan to improve profitability, BofA Merrill Lynch analyst Andrew Stimpson said the cost ambitions are greater than he expected, but he believes capital will continue to be an issue as the bank decided to not raise equity. Also, preliminary Q2 underlying results missed consensus, noted Stimpson, who keeps an Underperform rating on Deutsche Bank shares with many details of the company's plan still outstanding.
07/08/19
RBCM
07/08/19
NO CHANGE
RBCM
Underperform
Deutsche Bank business review 'more radical than expected', says RBC Capital
RBC Capital analyst Anke Reingen raised her price target on Deutsche Bank to EUR8 from EUR7.50, saying its transformation plan announced over the weekend is "more radical than expected" and could support its shares over the short term. The analyst maintained her Underperform rating however, noting that the bank's execution will be key, while also pointing to the company's pushed out projections for improvement in profitability.
BBD Banco Bradesco
$7.87

(0.00%)

12/11/18
HSBC
12/11/18
DOWNGRADE
HSBC
Reduce
Banco Bradesco downgraded to Reduce from Hold at HSBC
02/26/19
SCOT
02/26/19
DOWNGRADE
SCOT
Underperform
Banco Bradesco downgraded to Underperform from Sector Perform at Scotiabank
06/10/19
GSCO
06/10/19
INITIATION
Target $8
GSCO
Sell
Banco Bradesco initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Tito Labarta started Banco Bradesco with a Sell rating and $8 price target. He thinks further improvements in the company's profitability "will be harder to come by," given historically low interest rates." The analyst also thinks the bank is at a relative disadvantage to peers in the acquiring business, as it does not have full control of its merchant acquirer, Cielo. Labarta initiated coverage on Brazilian Financials with a cautious outlook on the banks, but a "more optimistic" view for non-bank financials.
08/07/19
MSCO
08/07/19
UPGRADE
MSCO
Overweight
Banco Bradesco upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Jorge Kuri upgraded Banco Bradesco to Overweight from Equal Weight.
JNJ Johnson & Johnson
$131.84

(0.00%)

08/27/19
FBCO
08/27/19
NO CHANGE
Target $156
FBCO
Outperform
Opioid ruling reduces uncertainty, helps J&J move higher, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Johnson & Johnson appeared to react favorably to Oklahoma opioid ruling, due in part, to the $572M penalty being substantially lower than the $17B sought by State prosecutors. The analyst believes the decision helped reduce the range of uncertainty related to the potential opioid-related liability Johnson & Johnson could face, specifically in Oklahoma, if not across the U.S. more broadly. Miksic reiterates an Outperform rating and $156 target on the shares.
08/27/19
JPMS
08/27/19
NO CHANGE
JPMS
Neutral
Johnson & Johnson verdict well below feared worst case, says JPMorgan
The $572M verdict against Johnson & Johnson in Oklahoma came in well below the feared worst case, as investor expectations for the verdict increased over the past few weeks to over $1B, JPMorgan analyst Chris Schott tells investors in a research note. Further, the analyst believes the company has "strong legal grounding" to potentially overturn and/or reduce the verdict. Nonetheless, Schott still sees a more balanced risk/reward near-term for J&J shares and remain on the sidelines with a Neutral rating.
08/27/19
WELS
08/27/19
NO CHANGE
WELS
Outperform
Opioid ruling should assuage Johnson & Johnson investor fears, says Wells Fargo
Wells Fargo analyst Larry Biegelsen thinks decision in Oklahoma is a net positive for Johnson & Johnson in that the amount the judge ordered the company to pay - $572M - was well below the amount the plaintiffs requested - $17.5B. Further, the analyst notes that the amount was for abatement of the entire opioid crisis in Oklahoma, not just Johnson & Johnson's share of it, which seems like something the company should be able to overturn or reduce on appeal. Although J&J plans to appeal the ruling, Biegelsen expects the company to eventually settle this and other opioid cases. Big picture, he estimates Johnson & Johnson will eventually settle the opioid litigation for between $5B-10B payable over several years which admittedly is a rough guess at this time. He has an Outperform rating on the shares.
10/02/19
WELS
10/02/19
NO CHANGE
WELS
Outperform
J&J Ohio settlements suggest 'manageable' liability, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that Johnson & Johnson has announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admission of liability and removes the company from the federal trial scheduled to begin October 21, 2019 for a total of $20.4M. The analyst notes that after applying the total settlement amount to the populations of Cuyahoga and Summit counties and that to the total U.S. population of 327M, he arrives at a total settlement amount of $3.7B, which is well below his expected total settlement amount of $10B-$15B. Importantly, Biegelsen expects any settlement amount to be paid over a period of many years which will make the potential payments more manageable for Johnson & Johnson. He has an Outperform rating on the shares.
ASHR X-trackers Harvest CSI 300
$26.82

(0.00%)

ATVI Activision Blizzard
$54.10

(0.00%)

10/03/19
KEYB
10/03/19
NO CHANGE
KEYB
KeyBanc views Activision Blizzard's Call of Duty: Mobile datapoints as positive
KeyBanc analyst Tyler Parker notes that according to Sensortower, Activivision's "Call of Duty: Mobile" has accumulated over $2M in spend and 20M downloads within the first few days of release. This is relatively in line or above other battle royale games, or mobile games that have stemmed from established IP on console, he contends. The analyst continues to believe that the game has significant potential as a premium mobile game experience, and views initial datapoints as positive relative to his expectations of $20M for Q4.
10/02/19
10/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Charles Schwab (SCHW), TD Ameritrade (AMTD), and E-Trade (ETFC) double-downgraded to Underweight from Overweight at Barclays. 2. Monster Beverage (MNST) downgraded to Neutral from Buy at Guggenheim with analyst Laurent Grandet citing his view that the stock will be range-bound until the market can better gauge the impact of the upcoming U.S. launch of Coca-Cola (KO) Energy, which is planned for January. 3. Vermilion Energy (VET) downgraded to Sector Perform from Outperform at National Bank. 4. Activision Blizzard (ATVI) downgraded to Underperform from Market Perform at Bernstein with analyst Todd Juenger saying he cannot reconcile the current stock price with the company's risk-adjusted fundamentals. 5. Louisiana-Pacific (LPX) downgraded to Neutral from Buy at Longbow with analyst Garik Shmois saying oriented strand board pricing hasn't accelerated as quickly as we previously anticipated. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/19
10/02/19
DOWNGRADE
Target $43

Underperform
Activision Blizzard downgraded to Underperform at Bernstein
As previously reported, Bernstein analyst Todd Juenger downgraded Activision Blizzard to Underperform from Market Perform as he cannot reconcile the current stock price with the company's risk-adjusted fundamentals. Furthermore, the analyst believes the market is "paying too much for the hope" this is the trough and things can only get better. Juenger raised his price target on the stock to $43 from $41.
10/02/19
BERN
10/02/19
DOWNGRADE
BERN
Underperform
Activision Blizzard downgraded to Underperform from Market Perform at Bernstein
ROKU Roku
$108.06

(0.00%)

10/09/19
MACQ
10/09/19
UPGRADE
Target $130
MACQ
Outperform
Macquarie upgrades Roku to Outperform, sees tripling of sales by 2022
Macquarie analyst Tim Nollen upgraded Roku to Outperform from Neutral with a price target of $130, up from $110. The shares closed Tuesday up $1.75 to $108.00. The shift to connected television viewing that has been underway in the U.S. for the past few years will follow internationally in the coming years, Nollen tells investors in a research note. Roku has built a leading position in the U.S., and its devices will find a "ready market abroad," contends the analyst. However, he believes the bigger growth opportunity may be the company's smart TV operating system integrations. Nollen thinks Roku can grow its user base by three times to over 70M active accounts by 2022, from 31M currently. 72M subscribers by 2022 could drive Platform revenue to $2.3B and overall revenue of $2.7B, nearly tripling from 2019 guidance, says the analyst.
09/20/19
NEED
09/20/19
NO CHANGE
Target $150
NEED
Buy
Needham defends Roku, says competing successfully against media giants
Needham analyst Laura Martin commented on the recent weakness in Roku stock, telling investors in a research note that even if Roku's hardware sales "went to zero tomorrow," hardware sales represented a total of 5% of Roku's profit contribution and that the financial downside would be "minimal." Martin also argues that Roku's economic momentum is primarily driven by revenue share upside Roku will get from new SVOD services like Apple+ and Disney+ that must pay Roku to access their 30M OTT customers, and that Roku is a stronger competitor with more financial momentum and deeper moats, plus a well-established track record of competing successfully against media giants. She maintains a Buy rating and $150 price target on the stock.
09/20/19
09/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Roku (ROKU) initiated with a Sell at Pivotal Research. 2. Carvana (CVNA) initiated with an Outperform at Oppenheimer. 3. Zealand Pharma (ZEAL) and MyoKardia (MYOK) were initiated with a Buy at Guggenheim. 4. Wayfair (W) initiated with a Sell at Berenberg. 5. Eton Pharmaceuticals (ETON) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/09/19
MACQ
10/09/19
UPGRADE
MACQ
Outperform
Roku upgraded to Outperform from Neutral at Macquarie
NVDA Nvidia
$177.21

(0.00%)

10/07/19
RBCM
10/07/19
NO CHANGE
Target $217
RBCM
Outperform
Nvidia price target raised to $217 from $190 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Nvidia to $217 and kept his Outperform rating, saying he expects the stock to be the best performing large-cap name in his coverage universe within the next 6-9 months. The analyst cites indications of a pick-up in the gaming demand, which he sees as tracking ahead of the company's plans. Steves also believes that Nvidia's Data Center should recover in Q4 thanks to the product refresh announcement expected in the quarter, further supporting his forecast of expanding gross margins.
10/02/19
RHCO
10/02/19
NO CHANGE
Target $105
RHCO
Hold
Xilinx price target lowered to $105 from $127 at SunTrust
SunTrust analyst William Stein lowered his price target on Xilinx (XLNX) to $105 and kept his Hold rating, saying that he prefers market leader Nvidia (NVDA) in the compute arena for server acceleration. The analyst still sees Xilinx as an "excellent company" that is well positioned to deliver high returns and profitable growth over time, but he prefers a more opportune entry point during this "downturn part" of the cycle.
10/07/19
EVER
10/07/19
NO CHANGE
Target $225
EVER
Outperform
Nvidia price target raised to $225 from $185 at Evercore ISI
Evercore ISI analyst C.J. Muse said in a note before the open that he thinks it is understandable that investors have taken a cautious view on the future growth of Nvidia's Gaming franchise, though he sees a potential recovery coming in the second half and momentum continuing into 2020 and beyond in that part of the company's business. Muse sees at least a 15% compound annual growth rate for Gaming into 2022, led by Notebook Gaming growth, even without giving credit for any contributions from Cloud gaming via wins at CSPs and GeForce Alliance, which could be a source of added upside. The analyst, who now predicts Nvidia EPS approaching $9.25 in the 2021 timeframe, reiterated his Outperform rating on the shares and raised his price target to $225 from $185. Nvidia, which also saw its price target raised to $217 from $190 at RBC Capital this morning, is up 3% to $187.44 in early trading.
10/09/19
PIPR
10/09/19
NO CHANGE
Target $200
PIPR
Overweight
Nvidia's two biggest growth drivers are back, says Piper Jaffray
Piper Jaffray analyst Harsh Kumar believes Nvidia's (NVDA) two biggest growth drivers, namely gaming and data center, are back. Following a round of channel checks, the analyst says Nvidia is one of the best positioned semiconductor companies from a "company-specific catalyst perspective." Gaming, which represents around half of the company's revenue, appears to have settled following the GPU inventory correction, and the segment is setup for a seasonally strong second half of 2019, Kumar tells investors in a research note. In addition, the analyst is convinced Nvidia's data center business appears to have stabilized, and he sees growth in the segment moving forward. Further, Kumar thinks the Mellanox (MLNX) acquisition is on track to close by the end of calendar 2019. Lastly, based on Piper's teen survey results, the analyst believes video game interest remains high among U.S. teens. He keeps an Overweight rating on Nvidia with a $200 price target. The stock closed Tuesday down $7.10 to $177.23.
AAL American Airlines
$26.26

(0.00%)

09/06/19
BREN
09/06/19
INITIATION
Target $35
BREN
Buy
American Airlines initiated with a Buy at Berenberg
Berenberg analyst Adrian Yanoshik started American Airlines with a Buy rating and $35 price target.
07/30/19
IMPC
07/30/19
NO CHANGE
Target $41
IMPC
Outperform
American Airlines undervalued despite 737 Max groundings, says Imperial Capital
Imperial Capital analyst Michael Derchin says shares of American Airlines (AAL) are undervalued despite the groundings of Boeing's (BA) 737 Max. The stock is attractive with 737 MAX issues largely priced into the stock and upside potential on unit revenues amid low expectations, Derchin tells investors in a research note. He maintains an Outperform rating on American with a $41 price target.
07/29/19
MACQ
07/29/19
DOWNGRADE
MACQ
Neutral
Macquarie warns about pricing pressure among airlines from Southwest competition
Macquarie analyst Susan Donofrio downgraded American Airlines (AAL), Spirit Airlines (SAVE), Hawaiian Holdings (HA), and Alaska Air (ALK) to Neutral from Outperform as part of a broader industry note, saying the competitive environment for these airlines should become "choppy" in the fall of 2019 and in 2020 as Southwest (LUV) attempts to win back market share. The analyst believes that the latter's sizable domestic scope should lead to "unit revenue softness" within the overall pricing structure, through she maintains an Outperform rating on United Airlines (UAL), Delta (DAL) and Allegiant (ALGT) given their ongoing revenue initiatives and minimal overlap with Southwest.
09/06/19
BREN
09/06/19
INITIATION
BREN
Berenberg says big 4 airlines can generate cash, prefers American and Delta
As previously reported, Berenberg analyst Adrian Yanoshik initiated coverage of the four largest U.S. airlines, starting American Airlines (AAL) with a Buy rating and $35 price target, Delta Air Lines (DAL) with a Buy rating and $72 price target, United Continental (UAL) with a Hold rating and $95 price target and Southwest Airlines (LUV) with a Hold rating and $57 price target. Amid market worries over both capacity growth and demand weakness, his work suggests that U.S. airlines can generate free cash flow in "all scenarios but a 9/11-scale shock," Yanoshik tells investors. He thinks airline sector valuations reflect fears, but overlook broadly stable, albeit two-tiered, returns. He would buy American with valuation at multi-year lows as he estimates that American will narrow its margin gap to peers and thinks it debt burden is misunderstood. He would also buy Delta, which Yanoshik calls "arguably the highest-quality airline."

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

, SPX

S&P 500

$0.00

(0.00%)

20:46
10/15/19
10/15
20:46
10/15/19
20:46
Periodicals
China may retaliate if U.S. Congress passes bill supporting Hong Kong protesters 

Report from Bloomberg.

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$29.74

0.59 (2.02%)

, ABT

Abbott

$82.06

2.25 (2.82%)

20:25
10/15/19
10/15
20:25
10/15/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$29.74

0.59 (2.02%)

ABT

Abbott

$82.06

2.25 (2.82%)

USB

U.S. Bancorp

$53.73

0.47 (0.88%)

PNC

PNC Financial

$141.86

1.38 (0.98%)

BK

BNY Mellon

$44.37

0.47 (1.07%)

ALLY

Ally Financial

$32.03

0.68 (2.17%)

CMA

Comerica

$67.01

1.765 (2.71%)

FHN

First Horizon

$16.13

0.22 (1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 27

    Oct

  • 07

    Nov

  • 12

    Nov

RIO

Rio Tinto

$51.40

-0.43 (-0.83%)

20:17
10/15/19
10/15
20:17
10/15/19
20:17
Hot Stocks
Rio Tinto reports Q3 Pilbara iron ore output 87.3M tons, up 6% from last year »

Reports Q3 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNTX

Gentex

$26.98

0.65 (2.47%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Gentex initiated at Guggenheim »

Gentex initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 04

    Nov

VNE

Veoneer

$16.11

0.82 (5.36%)

20:16
10/15/19
10/15
20:16
10/15/19
20:16
Initiation
Veoneer initiated at Guggenheim »

Veoneer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VC

Visteon

$82.45

0.63 (0.77%)

20:15
10/15/19
10/15
20:15
10/15/19
20:15
Initiation
Visteon initiated at Guggenheim »

Visteon initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

DLPH

Delphi Technologies

$14.37

0.45 (3.23%)

20:14
10/15/19
10/15
20:14
10/15/19
20:14
Initiation
Delphi Technologies initiated at Guggenheim »

Delphi Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

BWA

BorgWarner

$37.74

0.68 (1.83%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
BorgWarner initiated at Guggenheim »

BorgWarner initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

LEA

Lear

$121.75

3.94 (3.34%)

20:13
10/15/19
10/15
20:13
10/15/19
20:13
Initiation
Lear initiated at Guggenheim »

Lear initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 04

    Nov

  • 10

    Dec

  • 11

    Dec

DFIN

Donnelley Financial Solutions

$10.54

0.035 (0.33%)

20:12
10/15/19
10/15
20:12
10/15/19
20:12
Initiation
Donnelley Financial Solutions initiated at B. Riley FBR »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

, TEVA

Teva

$6.96

0.22 (3.26%)

19:17
10/15/19
10/15
19:17
10/15/19
19:17
Periodicals
As part of proposed settlement, Teva offers $15B of free drugs, Bloomberg says »

The report also notes…

JNJ

Johnson & Johnson

$132.84

2.17 (1.66%)

TEVA

Teva

$6.96

0.22 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 07

    Nov

WAFD

Washington Federal

$36.81

0.15 (0.41%)

19:04
10/15/19
10/15
19:04
10/15/19
19:04
Earnings
Washington Federal reports Q4 EPS 66c, consensus 65c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

INGR

Ingredion

$81.17

0.94 (1.17%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Hot Stocks
Ingredion discloses malware affecting certain data centers »

Ingredion issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

19:01
10/15/19
10/15
19:01
10/15/19
19:01
Periodicals
Pelosi holds off on House vote over impeachment inquiry, Politico says »

House Speaker Nancy…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$298.89

2.88 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$14.40

0.02 (0.14%)

18:59
10/15/19
10/15
18:59
10/15/19
18:59
Hot Stocks
Petrobras signs charter contracts for two FPSO platforms »

Petrobras announced that …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SNBR

Sleep Number

$46.69

0.48 (1.04%)

, UAL

United Airlines

$87.90

0.9 (1.03%)

18:58
10/15/19
10/15
18:58
10/15/19
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Sleep…

SNBR

Sleep Number

$46.69

0.48 (1.04%)

UAL

United Airlines

$87.90

0.9 (1.03%)

MCK

McKesson

$138.17

4.01 (2.99%)

ABC

AmerisourceBergen

$83.18

1.6 (1.96%)

CAH

Cardinal Health

$47.93

1.16 (2.48%)

FULT

Fulton Financial

$15.90

0.19 (1.21%)

ETN

Eaton

$82.16

1.29 (1.60%)

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

MGM

MGM Resorts

$27.87

-0.1 (-0.36%)

JBHT

J.B. Hunt

$111.65

1.985 (1.81%)

IBKR

Interactive Brokers

$47.43

0.26 (0.55%)

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

NTRA

Natera

$39.21

1.01 (2.64%)

PRNB

Principia Biopharma

$29.88

0.7 (2.40%)

X

U.S. Steel

$11.43

0.27 (2.42%)

ARCE

Arco Platform

$48.15

0.75 (1.58%)

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 18

    Oct

KKR

KKR

$26.79

0.67 (2.57%)

, DB

Deutsche Bank

$7.79

0.235 (3.11%)

18:21
10/15/19
10/15
18:21
10/15/19
18:21
Periodicals
KKR, partners cancel Latitude Financial IPO, Reuters reports »

KKR (KKR) and its…

KKR

KKR

$26.79

0.67 (2.57%)

DB

Deutsche Bank

$7.79

0.235 (3.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 29

    Oct

  • 04

    Nov

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:20
10/15/19
10/15
18:20
10/15/19
18:20
Hot Stocks
Breaking Hot Stocks news story on Tradeweb Markets »

Tradeweb Markets sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:17
10/15/19
10/15
18:17
10/15/19
18:17
Syndicate
Tradeweb Markets files to sell 14.8M shares of Class A common stock »

Refinitiv will continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

TW

Tradeweb Markets

$39.79

-0.14 (-0.35%)

18:16
10/15/19
10/15
18:16
10/15/19
18:16
Earnings
Tradeweb Markets sees Q3 adjusted EPS 27c, consensus 25c »

Sees Q3 revenue $200.98M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 18

    Oct

EDIT

Editas Medicine

$20.30

0.48 (2.42%)

18:15
10/15/19
10/15
18:15
10/15/19
18:15
Hot Stocks
Editas Medicine, AskBio enter research collaboration over in vivo delivery »

Editas Medicine and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$114.78

2.43 (2.16%)

18:03
10/15/19
10/15
18:03
10/15/19
18:03
Periodicals
NV regulators want to ban Steve Wynn from NV casino industry, Reuters says »

The Nevada Gaming Control…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFIX

Stitch Fix

$20.83

-0.38 (-1.79%)

18:00
10/15/19
10/15
18:00
10/15/19
18:00
Hot Stocks
Stitch Fix director buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NTRA

Natera

$39.21

1.01 (2.64%)

17:48
10/15/19
10/15
17:48
10/15/19
17:48
Syndicate
Natera files to sell $175M of common stock »

J.P. Morgan, Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$3.36

0.2 (6.33%)

17:45
10/15/19
10/15
17:45
10/15/19
17:45
Earnings
Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.